236 related articles for article (PubMed ID: 32840062)
1. Association of Anti-Topoisomerase I Antibodies of the IgM Isotype With Disease Progression in Anti-Topoisomerase I-Positive Systemic Sclerosis.
Boonstra M; Bakker JA; Grummels A; Ninaber MK; Ajmone Marsan N; Wortel CM; Huizinga TWJ; Jordan S; Hoffman-Vold AM; Distler O; Toes REM; Scherer HU; de Vries-Bouwstra JK
Arthritis Rheumatol; 2020 Nov; 72(11):1897-1904. PubMed ID: 32840062
[TBL] [Abstract][Full Text] [Related]
2. IgM, IgG, and IgA anti-DNA topoisomerase I antibodies in systemic sclerosis.
Martínez-Cordero E; Trejo AP; León DE
J Clin Lab Anal; 2009; 23(6):408-16. PubMed ID: 19927342
[TBL] [Abstract][Full Text] [Related]
3. Anti-DNA topoisomerase II alpha autoantibodies in Japanese patients with systemic sclerosis.
Hayakawa I; Hasegawa M; Takehara K; Sato S
Arch Dermatol Res; 2005 Oct; 297(4):180-3. PubMed ID: 16180014
[TBL] [Abstract][Full Text] [Related]
4. Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody.
Perera A; Fertig N; Lucas M; Rodriguez-Reyna TS; Hu P; Steen VD; Medsger TA
Arthritis Rheum; 2007 Aug; 56(8):2740-6. PubMed ID: 17665460
[TBL] [Abstract][Full Text] [Related]
5. A recombinant topoisomerase I ELISA: screening for IgG, IgM and IgA anti-topo I autoantibodies in human sera.
Verheijen R; de Jong BA; van Venrooij WJ
Clin Exp Immunol; 1992 Sep; 89(3):456-60. PubMed ID: 1325307
[TBL] [Abstract][Full Text] [Related]
6. Functionally Active Antibodies to the Angiotensin II Type 1-Receptor Measured by a Luminometric Bioassay Do Not Correlate With Clinical Manifestations in Systemic Sclerosis: A Comparison With Antibodies to Vascular Receptors and Topoisomerase I Detected by ELISA.
Bankamp L; Preuß B; Pecher AC; Beucke N; Henes J; Klein R
Front Immunol; 2021; 12():786039. PubMed ID: 34956217
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis.
Kuwana M; Kaburaki J; Mimori T; Kawakami Y; Tojo T
Arthritis Rheum; 2000 May; 43(5):1074-84. PubMed ID: 10817562
[TBL] [Abstract][Full Text] [Related]
8. Anti-topoisomerase I antibodies in silica-associated systemic sclerosis. A model for autoimmunity.
McHugh NJ; Whyte J; Harvey G; Haustein UF
Arthritis Rheum; 1994 Aug; 37(8):1198-205. PubMed ID: 8053959
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic value of anti-topoisomerase I antibodies in a large monocentric cohort.
Hanke K; Dähnrich C; Brückner CS; Huscher D; Becker M; Jansen A; Meyer W; Egerer K; Hiepe F; Burmester GR; Schlumberger W; Riemekasten G
Arthritis Res Ther; 2009; 11(1):R28. PubMed ID: 19232127
[TBL] [Abstract][Full Text] [Related]
10. Clinical features of Japanese systemic sclerosis (SSc) patients negative for SSc-related autoantibodies: A single-center retrospective study.
Miyake M; Matsushita T; Takehara K; Hamaguchi Y
Int J Rheum Dis; 2020 Aug; 23(9):1219-1225. PubMed ID: 32662135
[TBL] [Abstract][Full Text] [Related]
11. Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis.
Hamaguchi Y
J Dermatol; 2010 Jan; 37(1):42-53. PubMed ID: 20175839
[TBL] [Abstract][Full Text] [Related]
12. The level of anti-topoisomerase I antibodies highly correlates with metacarpophalangeal and proximal interphalangeal joints flexion contractures in patients with systemic sclerosis.
Radić M; Martinović Kaliterna D; Ljutić D
Clin Exp Rheumatol; 2006; 24(4):407-12. PubMed ID: 16956431
[TBL] [Abstract][Full Text] [Related]
13. Direct binding of anti-DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis.
Hénault J; Tremblay M; Clément I; Raymond Y; Senécal JL
Arthritis Rheum; 2004 Oct; 50(10):3265-74. PubMed ID: 15476238
[TBL] [Abstract][Full Text] [Related]
14. Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis.
Hu PQ; Fertig N; Medsger TA; Wright TM
Arthritis Rheum; 2003 May; 48(5):1363-73. PubMed ID: 12746909
[TBL] [Abstract][Full Text] [Related]
15. Diversity and plasticity of the anti-DNA topoisomerase I autoantibody response in scleroderma.
Henry PA; Atamas SP; Yurovsky VV; Luzina I; Wigley FM; White B
Arthritis Rheum; 2000 Dec; 43(12):2733-42. PubMed ID: 11145031
[TBL] [Abstract][Full Text] [Related]
16. Molecular recognition patterns of anti-topoisomerase I-antibodies in patients with systemic sclerosis before and after autologous stem cell transplantation.
Glaeser L; Henes J; Kötter I; Vogel W; Kanz L; Klein R
Clin Exp Rheumatol; 2018; 36 Suppl 113(4):28-35. PubMed ID: 29465357
[TBL] [Abstract][Full Text] [Related]
17. Analysis of anti-topoisomerase I antibodies in patients with systemic sclerosis before and after autologous stem cell transplantation.
Henes J; Glaeser L; Kötter I; Vogel W; Kanz L; Klein R
Rheumatology (Oxford); 2017 Mar; 56(3):451-456. PubMed ID: 27940597
[TBL] [Abstract][Full Text] [Related]
18. Detection of anti-DNA topoisomerase I antibody by an enzyme-linked immunosorbent assay using overlapping recombinant polypeptides.
Kuwana M; Medsger TA; Wright TM
Clin Immunol Immunopathol; 1995 Sep; 76(3 Pt 1):266-78. PubMed ID: 7554448
[TBL] [Abstract][Full Text] [Related]
19. Frequency of circulating topoisomerase-I-specific CD4 T cells predicts presence and progression of interstitial lung disease in scleroderma.
Fava A; Cimbro R; Wigley FM; Liu QR; Rosen A; Boin F
Arthritis Res Ther; 2016 May; 18(1):99. PubMed ID: 27145754
[TBL] [Abstract][Full Text] [Related]
20. Is anti-topoisomerase I a serum marker of pulmonary involvement in systemic sclerosis?
Diot E; Giraudeau B; Diot P; Degenne D; Ritz L; Guilmot JL; Lemarié E
Chest; 1999 Sep; 116(3):715-20. PubMed ID: 10492277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
